C ▁technology ▁to ▁develop ▁its ▁own ▁product ▁candidates . ▁Product s ▁currently ▁in ▁clin ical - stage ▁development ▁include : ▁ ▁IM GN 8 5 3 , ▁( mir vet ux im ab ▁sor av t ans ine ) ▁target ing ▁FR α , ▁and ▁using ▁DM 4 . ▁IM GN 5 2 9 , ▁target ing ▁CD 3 7 ▁for ▁Non - H od g kin ▁l ym ph oma ▁( N HL ). ▁IM GN 2 8 9 , ▁target ing ▁E G FR ▁IM GN 7 7 9 , ▁a ▁CD 3 3 - Target ed ▁Ant ib ody - D rug ▁Con j ug ate ▁( AD C ) ▁with ▁a ▁new ▁DNA - Al k yl ating ▁agent ▁acts ▁on ▁A ML ▁C ells . ▁IM GN 6 3 2 , ▁anti - CD 1 2 3 ▁S AR 4 0 8 7 0 1 ▁in ▁collaboration ▁with ▁San of i ▁S AR 4 2 8 9 2 6 ▁in ▁collaboration ▁with ▁San of i ▁ ▁S AR 5 6 6 6 5 8 ▁in ▁collaboration ▁with ▁San of i ▁ ▁L Y 3 0 7 6 2 2 6 ▁in ▁collaboration ▁with ▁Eli ▁L illy ▁ ▁P CA 0 6 2 ▁in ▁collaboration ▁with ▁Nov art is ▁ ▁an ▁und is closed ▁ant ib ody ▁in ▁collaboration ▁with ▁Am gen ▁ ▁Coll abor ations ▁& ▁lic ens ing ▁The ▁company ▁also ▁select ively ▁out lic enses ▁limited ▁use ▁of ▁its ▁technology ▁to ▁other ▁companies . ▁Comp an